Chaung-U

Hestia Insight Inc. Appoints Advisory Board Member to Assist in Company Growth

Retrieved on: 
Thursday, January 5, 2023
West Virginia University, OTCQB, Hoffmann-La Roche, Merck & Co., Drug development, Merck, Barakat Pharmaceutical Group, Chaung-U, Growth, Massachusetts Institute of Technology, National Taiwan University, Bristol Myers Squibb, Virginia University, Marketing, Pharmaceutical industry

NEW YORK, NY, Jan. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Hestia Insight Inc. (OTCQB: HSTA) (“Hestia Insight” and the “Company”), a company focused on the development and operation of novel technologies in the healthcare and biotech sectors, as well as providing sales and marketing guidance and capital markets advisory services to its clients, today announced its appointment of an additional advisory board member to assist in the growth of the Company.

Key Points: 
  • NEW YORK, NY, Jan. 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Hestia Insight Inc. (OTCQB: HSTA) (“Hestia Insight” and the “Company”), a company focused on the development and operation of novel technologies in the healthcare and biotech sectors, as well as providing sales and marketing guidance and capital markets advisory services to its clients, today announced its appointment of an additional advisory board member to assist in the growth of the Company.
  • (Ted) Chaung, a seasoned independent healthcare consultant with broad experience in healthcare industry startups, new drug development, venture capital, and business development, in both the Taiwan and U.S. healthcare sectors, has joined the Company’s advisory board.
  • “We are excited to welcome the addition of Dr. Ted Chaung to our Advisory Board,”  stated Hestia Insight’s CEO and Chairman, Edward Lee.
  • We look forward to utilizing Dr. Chaung’s impressive background and skill set to assist with the growth of Hesta Insight.”